Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire · Oct 5, 2026
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis StudyDefense World · Oct 5, 2026
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis StudyMarketBeat · Oct 4, 2026
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common StockGlobeNewsWire · Sep 30, 2026
Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy?Defense World · Sep 30, 2026
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call TranscriptSeeking Alpha · Sep 29, 2026Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.17 | -$0.18 | Miss |
| May 7, 2026 | -$0.21 | -$0.18 | Beat |
| Mar 25, 2026 | -$0.21 | -$0.27 | Miss |
| Nov 7, 2025 | -$0.19 | -$0.24 | Miss |
| Aug 8, 2025 | -$0.21 | -$0.22 | Miss |
| May 8, 2025 | -$0.23 | -$0.15 | Beat |